Pictet Asset Management
JANX icon

Pictet Asset Management’s Janux Therapeutics JANX Stock Holding History

Pictet Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-272,251
Closed -$3.76M – 2149
2025
Q4 		$3.76M Sell
272,251
-322,580
-54% -$7.59M ﹤0.01% 829
2025
Q3 		$14.5M Sell
594,831
-76,654
-11% -$1.87M 0.01% 597
2025
Q2 		$15.5M Buy
671,485
+14,880
+2% +$392K 0.02% 569
2025
Q1 		$17.7M Buy
656,605
+271,808
+71% +$10.2M 0.02% 524
2024
Q4 		$20.6M Buy
+384,797
New +$20.4M 0.02% 495

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Pictet Asset Management's JANX Position: Q1 2026 in Review

Pictet Asset Management sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 272,251 shares — an estimated $3.76M sold.

Pictet Asset Management first reported a position in JANX in Q4 2024 and held it in 5 quarters. The position peaked at $20.6M in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Pictet Asset Management reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pictet Asset Management sold 272,251 Janux Therapeutics shares in Q1 2026, an estimated $3.76M.
  • Pictet Asset Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 5 quarters.
  • Pictet Asset Management's Janux Therapeutics position peaked at $20.6M in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.